Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.

Abstract

Rituximab, a chimeric monoclonal antibody directed against CD20 of B cells, has been reported to be effective in the treatment of B-cell lymphomas and malignant and nonmalignant plasma cell-dependent diseases. We describe a 30-year-old woman with refractory pemphigus vulgaris who experienced a partial remission after treatment with rituximab.

• Authors: Thomas G Salopek, Sarvesh Logsetty, Edward E Tredget
• Journal: Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 47 Issue 5 Pg. 785-8 (Nov 2002) ISSN: 0190-9622 [Print] United States
• PMID: 12399777 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Immunosuppressive Agents
• Rituximab
• Cyclophosphamide

Topics

• Adult
• Antibodies, Monoclonal (administration & dosage, therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Body Surface Area
• Cyclophosphamide (therapeutic use)
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Pemphigus (drug therapy, physiopathology)
• Plasmapheresis
• Rituximab